BACKGROUND: Standard of care therapy (SOCT) for the treatment of methicillin susceptible staphylococcal aureus (MSSA) infections requires multiple daily infusions. Despite questionable efficacy due to high protein binding, ceftriaxone (CTX) is frequently used for treatment of MSSA at Hines VA Hospital. OBJECTIVE: The objective of this study was to determine clinical and microbiological outcomes in patients with MSSA bacteremia treated with CTX compared to SOCT. SETTING: This retrospective study was conducted at the Edward Hines, Jr. VA Hospital which is a comprehensive health care center serving the veteran population of the greater metropolitan Chicago and northwest Indiana regions and is institutionally affiliated with the Loyola University Medical Center. The Hines VA provides medical care to over 56,000 veterans and operates approximately 500 hospital beds, including acute care and nursing home beds. METHOD: We conducted a retrospective cohort study of patients with MSSA bacteremia treated at Hines VA Hospital between January 2000 and September 2009. Patients who received either SOCT or CTX for >50% of the treatment course and for the appropriate duration were included. Patients who were on multiple antibiotics concurrently or who received <14 days of therapy were excluded. MAIN OUTCOME MEASURE: The primary outcome of this study is to compare clinical outcomes of patients with MSSA bacteremia who were treated with CTX compared to those who received standard of care agents. RESULTS: Ninety-three patients with MSSA bacteremia were included in the analysis. Fifty-one were treated with SOCT and 42 with CTX. There were no differences in microbiological cure between SOCT (94.1%) and CTX (95.2%) (p = 0.812). Clinical cure was similar between groups (74.5% for SOCT, 83.3% for CTX) (p = 0.303). CTX was used more often to treat Staphylococcus aureus bacteremia associated with osteomyelitis whereas endocarditis and central line associated infections were treated more frequently with SOCT (p = 0.01). More patients treated with CTX were managed in the ambulatory setting (64 vs. 24%; p = <0.001). There was a trend toward a longer hospital stay with SOCT. CONCLUSION: Clinical outcomes for MSSA bacteremia did not differ significantly between patients treated with CTX and SOCT. Findings suggest that CTX may be an alternative for outpatient management of MSSA bacteremia.
BACKGROUND: Standard of care therapy (SOCT) for the treatment of methicillin susceptible staphylococcal aureus (MSSA) infections requires multiple daily infusions. Despite questionable efficacy due to high protein binding, ceftriaxone (CTX) is frequently used for treatment of MSSA at Hines VA Hospital. OBJECTIVE: The objective of this study was to determine clinical and microbiological outcomes in patients with MSSA bacteremia treated with CTX compared to SOCT. SETTING: This retrospective study was conducted at the Edward Hines, Jr. VA Hospital which is a comprehensive health care center serving the veteran population of the greater metropolitan Chicago and northwest Indiana regions and is institutionally affiliated with the Loyola University Medical Center. The Hines VA provides medical care to over 56,000 veterans and operates approximately 500 hospital beds, including acute care and nursing home beds. METHOD: We conducted a retrospective cohort study of patients with MSSA bacteremia treated at Hines VA Hospital between January 2000 and September 2009. Patients who received either SOCT or CTX for >50% of the treatment course and for the appropriate duration were included. Patients who were on multiple antibiotics concurrently or who received <14 days of therapy were excluded. MAIN OUTCOME MEASURE: The primary outcome of this study is to compare clinical outcomes of patients with MSSA bacteremia who were treated with CTX compared to those who received standard of care agents. RESULTS: Ninety-three patients with MSSA bacteremia were included in the analysis. Fifty-one were treated with SOCT and 42 with CTX. There were no differences in microbiological cure between SOCT (94.1%) and CTX (95.2%) (p = 0.812). Clinical cure was similar between groups (74.5% for SOCT, 83.3% for CTX) (p = 0.303). CTX was used more often to treat Staphylococcus aureus bacteremia associated with osteomyelitis whereas endocarditis and central line associated infections were treated more frequently with SOCT (p = 0.01). More patients treated with CTX were managed in the ambulatory setting (64 vs. 24%; p = <0.001). There was a trend toward a longer hospital stay with SOCT. CONCLUSION: Clinical outcomes for MSSA bacteremia did not differ significantly between patients treated with CTX and SOCT. Findings suggest that CTX may be an alternative for outpatient management of MSSA bacteremia.
Authors: M Paul; N Zemer-Wassercug; O Talker; Y Lishtzinsky; B Lev; Z Samra; L Leibovici; J Bishara Journal: Clin Microbiol Infect Date: 2010-12-14 Impact factor: 8.067
Authors: Stephan Schmidt; Katharina Röck; Martina Sahre; Olaf Burkhardt; Martin Brunner; Maximilian T Lobmeyer; Hartmut Derendorf Journal: Antimicrob Agents Chemother Date: 2008-09-08 Impact factor: 5.191
Authors: Vance G Fowler; Jose M Miro; Bruno Hoen; Christopher H Cabell; Elias Abrutyn; Ethan Rubinstein; G Ralph Corey; Denis Spelman; Suzanne F Bradley; Bruno Barsic; Paul A Pappas; Kevin J Anstrom; Dannah Wray; Claudio Q Fortes; Ignasi Anguera; Eugene Athan; Philip Jones; Jan T M van der Meer; Tom S J Elliott; Donald P Levine; Arnold S Bayer Journal: JAMA Date: 2005-06-22 Impact factor: 56.272
Authors: Vance G Fowler; Maren K Olsen; G Ralph Corey; Christopher W Woods; Christopher H Cabell; L Barth Reller; Allen C Cheng; Tara Dudley; Eugene Z Oddone Journal: Arch Intern Med Date: 2003-09-22
Authors: V G Fowler; L L Sanders; D J Sexton; L Kong; K A Marr; A K Gopal; G Gottlieb; R S McClelland; G R Corey Journal: Clin Infect Dis Date: 1998-09 Impact factor: 9.079
Authors: Maya Beganovic; Jaclyn A Cusumano; Vrishali Lopes; Kerry L LaPlante; Aisling R Caffrey Journal: Open Forum Infect Dis Date: 2019-06-06 Impact factor: 3.835
Authors: Dustin R Carr; Usha Stiefel; Robert A Bonomo; Christopher J Burant; Sharanie V Sims Journal: Open Forum Infect Dis Date: 2018-05-18 Impact factor: 3.835
Authors: Laura Herrera-Hidalgo; Rafael Luque-Márquez; Aristides de Alarcon; Ana Belén Guisado-Gil; Belen Gutierrez-Gutierrez; Maria Dolores Navarro-Amuedo; Julia Praena-Segovia; Juan Manuel Carmona-Caballero; Elena Fraile-Ramos; Alicia Gutierrez-Valencia; Luis Eduardo Lopez-Cortes; Maria Victoria Gil-Navarro Journal: J Clin Med Date: 2022-03-11 Impact factor: 4.241